Molecular and cellular barriers limiting the effectiveness of antisense oligonucleotides

Biophysical Journal

Volumn 89, Issue 4, 2005, Pages 2286-2295

  Roth, Charles M ^a  

^a The State University of New Jersey   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA;

ARTICLE; BINDING AFFINITY; BINDING KINETICS; CELL; CELL BARRIER; DEGRADATION; GENE DISRUPTION; INTRACELLULAR TRANSPORT; MATHEMATICAL MODEL; MODEL; MOLECULAR BARRIER; MOLECULAR STABILITY; MOLECULE; PREDICTION; RNA BINDING; SYSTEMS MODEL;

EID: 25844526639     PISSN: 00063495     EISSN: None     Source Type: Journal    
DOI: 10.1529/biophysj.104.054080     Document Type: Article

References (44)

1. Opalinska, J. B., and A. M. Gewirtz. 2002. Nucleic-acid therapeutics: basic principles and recent applications. Nat. Rev. Drug Discov. 1:503-514.
2. Dean, N. M. 2001. Functional genomics and target validation approaches using antisense oligonucleotide technology. Curr. Opin. Biotechnol. 12:622-625.
3. Taylor, M. F., K. Wiederholt, and F. Sverdrup. 1999. Antisense oligonucleotides: a systematic high-throughput approach to target validation and gene function determination. Drug Discov. Today. 4:562-567.
4. Lee, L. K., and C. M. Roth. 2003. Antisense technology in molecular and cellular bioengineering. Curr. Opin. Biotechnol. 14:505-511.
5. Ramanathan, M., R. D. MacGregor, and C. A. Hunt. 1993. Predictions of effect for intracellular antisense oligodeoxyribonucleotides from a kinetic model. Antisense Res. Dev. 3:3-18.
6. Fennell, D. A. 1997. Quantitative antisense dose-response relationships: mathematical modeling of antisense action under steady-state conditions. Antisense Nucleic Acid Drug Dev. 7:49-53.
7. Fennell, D. A., and F. E. Cotter. 2001. A dynamical systems model to simulate the perturbation kinetics of gene expression by antisense oligonucleotides. J. Theor. Biol. 209:103-112.
8. Haruki, M., Y. Tsunaka, M. Morikawa, S. Iwai, and S. Kanaya. 2000. Catalysis by Escherichia coli ribonuclease HI is facilitated by a phosphate group of the substrate. Biochemistry. 39:13939-13944.
9. Jayaraman, A., S. P. Wallon, M. L. Yarmush, and C. M. Roth. 2001. Rational selection and quantitative evaluation of antisense oligonucleotides. Biochim. Biophys. Acta. 1520:105-114.
10. Yakubov, L. A., E. A. Deeva, V. F. Zarytova, E. M. Ivanova, A. S. Ryte, L. V. Yurchenko, and V. V. Vlassov. 1989. Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? Proc. Natl. Acad. Sci. USA. 86:6454-6458.
11. Nakai, D., T. Seita, T. Terasaki, S. Iwasa, Y. Shoji, Y. Mizushima, and Y. Sugiyama. 1996. Cellular uptake mechanism for oligonucleotides: involvement of endocytosis in the uptake of phosphodiester oligonucleotides by a human coloreclal adenocarcinoma cell line, HCT-15. J. Pharmacol. Exp. Ther. 278:1362-1372.
12. Beltinger, C., H. U. Saragovi, R. M. Smith, L. LeSauteur, N. Shah, L. DeDionisio, L. Christensen, A. Raible, L. Jarett, and A. M. Gewirtz. 1995. Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J. Clin. Invest. 95:1814-1823.
13. de Diesbach, P., F. N'Kuli, C. Berens, E. Sonveaux, M. Monsigny, A. C. Roche, and P. J. Courtoy. 2002. Receptor-mediated endocytosis of phosphodiester oligonucleotides in the HepG2 cell line: evidence for nonconventional intracellular trafficking. Nucleic Acids Res. 30:1512-1521.
14. Varga, C. M., K. Hong, and D. A. Lauffenburger. 2001. Quantitative analysis of synthetic gene delivery vector design properties. Mol. Ther. 4:438-446.
15. Zelphati, O., and F. C. Szoka Jr. 1996. Mechanism of oligonucleotide release from cationic liposomes. Proc. Natl. Acad. Sci. USA. 93:11493-11498.
16. Maksimenko, A. V., M. B. Gottikh, V. Helin, Z. A. Shabarova, and C. Malvy. 1999. Physico-chemical and biological properties of antisense phosphodiester oligonucleotides with various secondary structures. Nucleosides Nucleotides. 18:2071-2091.
17. Wallon, S. P., G. N. Stephanopoulos, M. L. Yarmush, and C. M. Roth. 2002. Thermodynamic and kinetic characterization of antisense oligodeoxynucleotide binding to a structured mRNA. Biophys. J. 82:366-377.
18. Ledley, T. S., and F. D. Ledley. 1994. Multicompartment, numerical model of cellular events in the pharmacokinetics of gene therapies. Hum. Gene Ther. 5:679-691.
19. Banks, G. A., R. J. Roselli, R. Chen, and T. D. Giorgio. 2003. A model for the analysis of nonviral gene therapy. Gene Ther. 10:1766-1775.
20. Lodish, H., D. Baltimore, A. Berk, S. L. Zipursky, P. Matsudaira, and J. Damell. 1995. Molecular Cell Biology. W. H. Freeman and Company, New York.
21. Wu-Pong, S. 1996. The role of multivalent cations in oligonucleotide cellular uptake. Biochem. Mol. Biol. Int. 39:511-519.
22. Leonetti, J. P., P. Machy, G. Degols, B. Lebleu, and L. Leserman. 1990. Antibody-targeted liposomes containing oligodeoxyribonucleotides complementary to viral RNA selectively inhibit viral replication. Proc. Natl. Acad. Sci. USA. 87:2448-2451.
23. Zelphati, O., J. L. Imbach, N. Signoret, G. Zon, B. Rayner, and L. Leserman. 1994. Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms. Nucleic Acids Res. 22:4307-4314.
24. Semple, S. C., S. K. Klimuk, T. O. Harasym, N. Dos Santos, S. M. Ansell, K. F. Wong, N. Maurer, H. Stark, P. R. Cullis, M. J. Hope, and P. Scherrer. 2001. Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim. Biophys. Acta. 1510:152-166.
25. Lee, H., J. H. Jeong, and T. G. Park. 2001. A new gene delivery formulation of polyethylenimine/DNA complexes coated with PEG conjugated fusogenic peptide. J. Control. Release. 76:183-192.
26. Garcia-Chaumont, C., O. Seksek, J. Grzybowska, E. Borowski, and J. A. Bolard. 2000. Delivery systems for antisense oligonucleotides. Pharmacol. Ther. 87:255-277.
27. Roth, C. M., and S. Sundaram. 2004. Engineering synthetic vectors for DNA delivery: insights from intracellular pathways. Annu. Rev. Biomed. Eng. 6:397-426.
28. Raghavan, A., R. L. Ogilvie, C. Reilly, M. L. Abelson, S. Raghavan, J. Vasdewani, M. Krathwohl, and P. R. Bohjanen. 2002. Genome-wide analysis of mRNA decay in resting and activated primary human T lymphocytes. Nucleic Acids Res. 30:5529-5538.
29. Yang, E., E. van Nimwegen, M. Zavolan, N. Rajewsky, M. Schroeder, M. Magnasco, and J. E. Darnell Jr. 2003. Decay rates of human mRNAs: correlation with functional characteristics and sequence attributes. Genome Res. 13:1863-1872.
30. Ho, S. P., Y. Bao, T. Lesher, R. Malhotra, L. Y. Ma, S. J. Fluharty, and R. R. Sakai. 1998. Mapping of RNA accessible sites for anti-sense experiments with oligonucleotide libraries. Nat. Biotechnol. 16:59-63.
31. Milner, N., K. U. Mir, and E. M. Southern. 1997. Selecting effective antisense reagents on combinatorial oligonuculeotide arrays. Nat. Biotechnol. 15:537-541.
32. Mathews, D. H., M. E. Burkard, S. M. Freier, J. R. Wyatt, and D. H. Turner. 1999. Predicting oligonucleotide affinity to nucleic acid targets. RNA. 5:1458-1469.
33. Walton, S. P., G. N. Stephanopoulos, M. L. Yarmush, and C. M. Roth. 1999. Prediction of antisense oligonucleotide binding affinity to a structured RNA target. J. Biochem. Microbiol. Technol. Eng. 65:1-9.
34. Elayadi, A. N., D. A. Braasch, and D. R. Corey. 2002. Implications of high-affinity hybridization by locked nucleic acid oligomers for inhibition of human telomerase. Biochemistry. 41:9973-9981.
35. Barnes 3rd, T. W., and D. H. Turner. 2001. Long-range cooperativity in molecular recognition of RNA by oligodeoxynucleotides with multiple CS-(1-propynyl) pyrimidines. J. Am. Chem. Soc. 123:4107-4118.
36. Zhou, W., and S. Agrawal. 1998. Mixed-backbone oligonucleotides as second-generation antisense agents with reduced phosphorothioate-related side effects. Bioorg. Med. Chem. Lett. 8:3269-3274.
37. Esposito, W. R., and C. A. Floudas. 2000. Global optimization for the parameter estimation of differential-algebraic systems. Ind. Eng. Chem. Res. 39:1291-1310.
38. Dheur, S., N. Dias, A. van Aerschot, P. Herdewijn, T. Bettinger, J. S. Remy, C. Helene, and E. T. Saison-Behmoaras. 1999. Polyethylenimine but not cationic lipid improves antisense activity of 3́-capped phosphodiester oligonucleotides. Antisense Nucleic Acid Drug Dev. 9:515-525.
39. Vickers, T. A., S. Koo, C. F. Bennett, S. T. Crooke, N. M. Dean, and B. F. Baker. 2003. Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J. Biol. Chem. 278:7108-7118.
40. Elbashir, S. M., J. Harborth, W. Lendeckel, A. Yalcin, K. Weber, and T. Tuschl. 2001. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411:494-498.
41. Scherr, M., M. A. Morgan, and M. Eder. 2003. Gene silencing mediated by small interfering RNAs in mammalian cells. Curr. Med. Chem. 10:245-256.
42. Lauffenburger, D. A., and J. Linderman. 1993. Receptors: Models for Binding, Trafficking, and Signalling. Oxford University Press, New York.
43. Temsamani, J., M. Kubert, J. Tang, A. Padmapriya, and S. Agrawal. 1994. Cellular uptake of oligodeoxynucleotide phosphorothioates and their analogs. Antisense Res. Dev. 4:35-42.
44. Hawley, P., and I. Gibson. 1996. Interaction of oligodeoxynucleotides with mammalian cells. Antisense Nucleic Acid Drug Dev. 6:185-195.